The rationale of using metformin and chloroquine in order to disrupt the metabolism of IDH1-mutated solid tumors and to inhibit tumor growth was not supported by our clinical data, since ten out of twelve patients showed tumor progression during study treatment. This evidence concerns the gene IDH1 and neoplasm.